Chylomicron News and Research

RSS

Familial Chylomicronemia Syndrome: How HCP’s can Support Patients with Rare Diseases

Dr Robert Cramb gives an introduction to the rare disease FCS, and how HCP's can best advise and support patients with the condition.

15 May 2018

Study provides new insight into complex interchange that can raise blood levels of fat in type 1 diabetes

Researchers have new insight into the complex interchange that can raise blood levels of unhealthy lipids, or fat, in type 1 diabetes, and early evidence that a drug under study to block cancer cell growth can restore healthier levels.

8 Feb 2016

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).

6 Jul 2015

Researchers explore association between vitamin A and neonatal health

The impact vitamin A has on newborns is virtually unknown, but Penn State nutrition researchers have published two papers that may provide a framework for future investigations of the vitamin and neonatal health.

30 Oct 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.

6 May 2014

Isis Pharmaceuticals reports final data from ISIS-APOCIIIRx Phase 2 study in patients with FCS

Isis Pharmaceuticals, Inc. announced the final data from its Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, or FCS.

2 May 2014

Scientist receives grant to study biochemical fate of nanoemulsion-based food delivery systems in GI tract

Food scientist Hang Xiao of the University of Massachusetts Amherst recently received a four-year, $491,220 grant to study the biochemical fate of nanoemulsion-based food delivery systems in the gastrointestinal (GI) tract, hoping to re-shape them and enhance the absorption of beneficial food components encapsulated in delivery systems.

20 Jan 2014

ApoA-V as a contributor to dyslipidemia in obese children

Insulin may be an important regulator of serum apolipoprotein A-V levels in obese people and may contribute to the development of obesity-associated dyslipidemia, say Japanese researchers.

27 Sep 2012

LPL deficiency treatment poised to be first gene therapy in Europe

For the first time, the European Medicines Agency has recommended gene therapy for approval in Europe.

26 Jul 2012

Gene therapy improves chylomicron metabolism in LPLD patients

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today data demonstrating that one-time administration of the gene therapy Glybera (alipogene tiparvovec) is able to markedly improve chylomicron (fat particles in the blood) metabolism following consumption of a low fat meal.

29 Mar 2012

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

25 Aug 2011

AMT receives CHMP opinion on Glybera Marketing Authorisation Application

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.

24 Jun 2011

AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.

20 May 2011

Angptl4 protein deficiency could promote inflammatory response in people who consume high saturated fat

A new report in the December Cell Metabolism identifies a protein without which diets high in saturated fat lead to a massive inflammatory response that can prove fatal. The studies in mice suggest that deficiencies in this protective pathway could promote inflammation in those who regularly consume high levels of saturated fat.

1 Dec 2010

Tocotrienols can help reduce triglyceride levels

Scientists from Singapore found that tocotrienols, which are members of the Vitamin E family, are effective in lowering the levels of triglyceride, a form of fat in the blood. High levels of triglyceride are closely linked to an increased risk of cardiovascular and metabolic diseases.

18 Oct 2010

Amsterdam Molecular first half 2010 net loss in line with last year

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2010.

31 Aug 2010

Amsterdam Molecular Therapeutics commences preregistration trial for Glybera

Amsterdam Molecular Therapeutics announced today the treatment of the first patient in a preregistration clinical trial with Glybera. This gene therapy product targets lipoprotein lipase deficiency (LPLD), a seriously debilitating and potentially lethal disease.

7 May 2009

Fat-free diet reduces liver fat in fat-free mice

Researchers at UT Southwestern Medical Center have uncovered crucial clues about a paradoxical disease in which patients with no body fat develop many of the health complications usually found in obese people.

3 Feb 2009

Not all trans fats are bad for you

University of Alberta researcher Flora Wang found that a diet with enriched levels of trans vaccenic acid (VA) - a natural animal fat found in dairy and beef products - can reduce risk factors associated with heart disease, diabetes and obesity

3 Apr 2008

Protein CD36 may be important to future weight-loss strategies

Researchers at Washington University School of Medicine in St. Louis have found that a protein absorbs lipids in the upper part of the intestine, and they believe its key role in this process may provide a novel approach for obesity treatment in the future.

9 Jul 2007